PL373763A1 - Pochodne 2,6-chinolinylowe i 2,6-naftylowe, sposoby ich wytwarzania i ich zastosowanie jako inhibitorów VLA-4 - Google Patents

Pochodne 2,6-chinolinylowe i 2,6-naftylowe, sposoby ich wytwarzania i ich zastosowanie jako inhibitorów VLA-4

Info

Publication number
PL373763A1
PL373763A1 PL03373763A PL37376303A PL373763A1 PL 373763 A1 PL373763 A1 PL 373763A1 PL 03373763 A PL03373763 A PL 03373763A PL 37376303 A PL37376303 A PL 37376303A PL 373763 A1 PL373763 A1 PL 373763A1
Authority
PL
Poland
Prior art keywords
vla
quinolinyl
inhibitors
preparing
processes
Prior art date
Application number
PL03373763A
Other languages
English (en)
Inventor
Marie-Agnes Lassoie
Laurent Knerr
Thierry Demaude
Laveleye Françoise De
Thierry Kogej
Luc Quere
Sylvain Routier
Gerald Guillaumet
Original Assignee
Ucb, S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucb, S.A. filed Critical Ucb, S.A.
Publication of PL373763A1 publication Critical patent/PL373763A1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/63—Esters of sulfonic acids
    • C07C309/64—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms
    • C07C309/65—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms of a saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14—Radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Quinoline Compounds (AREA)
PL03373763A 2002-04-30 2003-04-15 Pochodne 2,6-chinolinylowe i 2,6-naftylowe, sposoby ich wytwarzania i ich zastosowanie jako inhibitorów VLA-4 PL373763A1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP02009746 2002-04-30

Publications (1)

Publication Number Publication Date
PL373763A1 true PL373763A1 (pl) 2005-09-19

Family

ID=29286106

Family Applications (1)

Application Number Title Priority Date Filing Date
PL03373763A PL373763A1 (pl) 2002-04-30 2003-04-15 Pochodne 2,6-chinolinylowe i 2,6-naftylowe, sposoby ich wytwarzania i ich zastosowanie jako inhibitorów VLA-4

Country Status (24)

Country Link
US (2) US7638630B2 (pl)
EP (2) EP1870402A1 (pl)
JP (1) JP2005535583A (pl)
KR (1) KR100841165B1 (pl)
CN (2) CN101200450A (pl)
AR (1) AR039341A1 (pl)
AT (1) ATE384699T1 (pl)
AU (1) AU2003232472B2 (pl)
BR (1) BR0309719A (pl)
CA (1) CA2484954C (pl)
CO (1) CO5450243A1 (pl)
CU (1) CU23415B7 (pl)
DE (1) DE60318839T2 (pl)
ES (1) ES2298543T3 (pl)
IL (1) IL164516A0 (pl)
MX (1) MXPA04010673A (pl)
MY (1) MY135218A (pl)
NO (1) NO20045234L (pl)
NZ (1) NZ536180A (pl)
PL (1) PL373763A1 (pl)
RU (1) RU2315041C2 (pl)
TW (2) TWI268278B (pl)
WO (1) WO2003093237A1 (pl)
ZA (1) ZA200408447B (pl)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7638630B2 (en) * 2002-04-30 2009-12-29 Ucb Pharma S.A. 2,6-quinolinyl and 2,6-naphthyl derivatives, processes for preparing them and their uses as VLA-4 inhibitors
US7153889B2 (en) 2002-11-12 2006-12-26 Abbott Laboratories Bicyclic-substituted amines as histamine-3 receptor ligands
CN100436429C (zh) * 2003-02-20 2008-11-26 味之素株式会社 具有喹唑二酮骨架的苯丙氨酸衍生物的制造方法及制造中间体
US7098222B2 (en) 2004-05-12 2006-08-29 Abbott Laboratories Bicyclic-substituted amines having cyclic-substituted monocyclic substituents
US7145005B2 (en) 2004-05-12 2006-12-05 Abbott Laboratories 2-(6-{2-[(2R)-2-Methyl-1-pyrrolidin-1-yl]-ethyl}-2-naphthalen-2-yl)-2H-pyridazin-3-one salts and their preparation
US7205316B2 (en) 2004-05-12 2007-04-17 Abbott Laboratories Tri- and bi-cyclic heteroaryl histamine-3 receptor ligands
EA013080B1 (ru) * 2005-06-09 2010-02-26 Юсб Фарма С.А. 2,6-хинолинильные производные, способы их получения и их применение
ES2391910T3 (es) 2006-11-14 2012-12-03 Santen Pharmaceutical Co., Ltd Derivado de 1,2-dihidroquinolina que tiene un grupo (fenil sustituido o heterociclil sustituido)carboniloxi-alquilo inferior y un grupo fenilo introducido por éster como sustituyentes
WO2008125210A1 (en) * 2007-04-12 2008-10-23 Ucb Pharma, S.A. Quinoline and naphthalene derivatives, processes for their preparation and their use in treatment of inflammatory diseases
WO2008125215A1 (en) * 2007-04-12 2008-10-23 Ucb Pharma, S.A. Bicyclic and heterobicyclic derivatives, processes for preparing them and their uses
WO2008138592A1 (en) * 2007-05-14 2008-11-20 Ucb Pharma, S.A. Bicyclic and heterobicyclic derivatives, processes for preparing them and their uses
WO2008138615A1 (en) * 2007-05-16 2008-11-20 Ucb Pharma, S.A. Bicyclic and heterobicyclic derivatives, processes for preparing them and their uses
US7902181B2 (en) * 2007-12-12 2011-03-08 Astrazeneca Ab Compounds 010
EP2085407A1 (en) 2008-02-04 2009-08-05 Sahltech I Göteborg AB Treatment of idiopathic thrombocytopenic purpura
CA2724055C (en) 2008-05-12 2016-08-02 Santen Pharmaceutical Co., Ltd. Glucocorticoid receptor agonist comprising 2,2,4-trimethyl-6-phenyl-1,2 -dihydroquinoline derivatives having substituted oxy group
EP2467159A1 (en) 2009-08-20 2012-06-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Vla-4 as a biomarker for prognosis and target for therapy in duchenne muscular dystrophy
US20150368213A1 (en) * 2014-06-20 2015-12-24 The University of Montana, Missoula, MT Novel Inhibitors of System Xc-
BR112017013465A2 (pt) * 2014-12-24 2018-03-06 Lg Chem, Ltd derivado de biarila, e, composição farmacêutica.
WO2018119142A1 (en) 2016-12-21 2018-06-28 Amgen Inc. Anti-tnf alpha antibody formulations
ES3013256T3 (en) 2018-10-30 2025-04-11 Gilead Sciences Inc Imidazo[1,2-a]pyridine derivatives as alpha4beta7 integrin inhibitors for the treatment of inflammatory diseases
FI3873884T3 (fi) 2018-10-30 2025-02-24 Gilead Sciences Inc 3-(kinolin-8-yyli)-1,4-dihydropyrido[3,4-d]pyrimidiini-2,4-dionijohdannaisia alfa-4-beta-7-integriinin estäjinä tulehdussairauksien hoidossa
JP7189368B2 (ja) 2018-10-30 2022-12-13 ギリアード サイエンシーズ， インコーポレイテッド アルファ４ベータ７インテグリンの阻害のための化合物
EP3873605B1 (en) 2018-10-30 2024-10-23 Gilead Sciences, Inc. Compounds for inhibition of alpha4beta7 integrin
WO2021030438A1 (en) 2019-08-14 2021-02-18 Gilead Sciences, Inc. Compounds for inhibition of alpha 4 beta 7 integrin
JP7635962B2 (ja) * 2021-01-12 2025-02-26 国立大学法人山口大学 フルオロアルキル置換ビニルフルオロアルカンスルホニルアミドの製造方法
WO2022162164A1 (en) 2021-01-29 2022-08-04 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of assessing the risk of developing progressive multifocal leukoencephalopathy in patients treated with vla-4 antagonists
CN116410136B (zh) * 2023-03-03 2025-07-11 五邑大学 一种喹啉衍生物及其制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE208376T1 (de) * 1992-08-19 2001-11-15 Pfizer Substituierte benzylamin-stickstoff enthaltende nichtaromatische heterocyclen
US5550139A (en) * 1994-01-03 1996-08-27 The Wichita State University Serine protease inhibitors
JP2920741B2 (ja) * 1994-12-14 1999-07-19 参天製薬株式会社 新規１，３−ジアルキルウレア誘導体
DE69528197T2 (de) * 1994-12-14 2003-06-05 Santen Pharmaceutical Co., Ltd Neue 1,3-dialkylharnstoff-derivate
JPH0987291A (ja) * 1995-09-26 1997-03-31 Wakamoto Pharmaceut Co Ltd 新規なアラニン誘導体
CA2279977A1 (en) 1997-02-04 1998-08-06 John S. Kiely 4-substituted-quinoline derivatives and 4-substituted-quinoline combinatorial libraries
AR016133A1 (es) * 1997-07-31 2001-06-20 Wyeth Corp Compuesto de carbamiloxi que inhiben la adhesion de leucocitos mediada por vla-4, compuestos que son prodrogas de dichos compuestos, composicionfarmaceutica, metodo para fijar vla-4 a una muestra biologica, metodo para el tratamiento de una condicion inflamatoria
EP1005445B1 (en) 1997-08-22 2004-05-26 F. Hoffmann-La Roche Ag N-alkanoylphenylalanine derivatives
US6608084B1 (en) 1998-08-26 2003-08-19 Aventis Pharma Ltd. Aza-bicycles which modulate the inhibition of cell adhesion
JP2002543194A (ja) * 1999-04-28 2002-12-17 ドクター・レディーズ・ラボラトリーズ・リミテッド 置換二環系ヘテロ環化合物、その製造方法、並びに抗肥満症及び抗高コレステロール血症剤としてのこれらの使用
US6280442B1 (en) * 1999-09-01 2001-08-28 Sdgi Holdings, Inc. Multi-axial bone screw assembly
US6399599B1 (en) * 1999-10-13 2002-06-04 Novartis Ag Substituted 2-oxo-1,4-diazacycloalkanes
US7638630B2 (en) * 2002-04-30 2009-12-29 Ucb Pharma S.A. 2,6-quinolinyl and 2,6-naphthyl derivatives, processes for preparing them and their uses as VLA-4 inhibitors
EA013080B1 (ru) 2005-06-09 2010-02-26 Юсб Фарма С.А. 2,6-хинолинильные производные, способы их получения и их применение

Also Published As

Publication number Publication date
MY135218A (en) 2008-02-29
TWI267508B (en) 2006-12-01
NZ536180A (en) 2005-04-29
US20080064720A1 (en) 2008-03-13
WO2003093237A1 (en) 2003-11-13
CA2484954A1 (en) 2003-11-13
IL164516A0 (en) 2005-12-18
CN1649842A (zh) 2005-08-03
AR039341A1 (es) 2005-02-16
AU2003232472B2 (en) 2008-09-18
RU2315041C2 (ru) 2008-01-20
CO5450243A1 (es) 2004-10-29
EP1501801A1 (en) 2005-02-02
DE60318839D1 (de) 2008-03-13
BR0309719A (pt) 2005-02-09
CU23415B7 (es) 2009-09-08
KR100841165B1 (ko) 2008-06-24
AU2003232472A1 (en) 2003-11-17
TW200404061A (en) 2004-03-16
CA2484954C (en) 2010-02-09
CN101200450A (zh) 2008-06-18
ES2298543T3 (es) 2008-05-16
JP2005535583A (ja) 2005-11-24
TW200616960A (en) 2006-06-01
NO20045234L (no) 2005-01-18
TWI268278B (en) 2006-12-11
US7638630B2 (en) 2009-12-29
ZA200408447B (en) 2006-07-26
US20100105681A1 (en) 2010-04-29
RU2004135304A (ru) 2005-07-10
EP1870402A1 (en) 2007-12-26
ATE384699T1 (de) 2008-02-15
KR20040106425A (ko) 2004-12-17
MXPA04010673A (es) 2005-09-30
EP1501801B1 (en) 2008-01-23
DE60318839T2 (de) 2009-01-22

Similar Documents

Publication Publication Date Title
PL373763A1 (pl) Pochodne 2,6-chinolinylowe i 2,6-naftylowe, sposoby ich wytwarzania i ich zastosowanie jako inhibitorów VLA-4
IL164597A0 (en) Substituted 3-amino-thienoÄ2,3-bÜpyridine-2-carboxylic acid amide compounds and processes for preparing and their uses
IL183568A (en) Process for making 7,8-dihydro-5 h-patridine-6-onh
IL191926A0 (en) Novel thiophenylglycoside derivatives, methods for production thereof, medicaments comprising said compounds and use thereof
PL376524A1 (pl) Nowe hydroksyindole, ich zastosowanie jako inhibitorów fosfodiesterazy 4 i sposób ich wytwarzania
AU2003233010A8 (en) Process for the preparation of 3,3,4,4-tetrafluoropyrrolidine and derivatives thereof
AU2003221270A8 (en) Nanocomposites: products, process for obtaining them and uses thereof
IL191711A0 (en) 1-orthofluorophenyl substituted 1,2,5-thiazolidinedione derivatives as ptp-as inhibitors
PL371279A1 (pl) Pochodne acylo-4-karboksyfenylo-mocznika, sposób ich wytwarzania i ich zastosowanie
HRP20050328A2 (en) Process for the preparation of (s,s)-cis-2-benzhyd
ZA200408423B (en) Novel tetrahydropyridine derivatives as renin inhibitors.
GB0504952D0 (en) Process for producing arylamine
AU2003212310A1 (en) (4,2-disubstituted-thiazol-5-yl)amine compounds as pde7 inhibitors
PL371319A1 (pl) Pochodne kumaryny, sposób ich wytwarzania i ich zastosowanie
PT1560815E (pt) Novas diamidas do ácido pirimidino-4,6-dicarboxílico para a inibição selectiva de colagenases
IL158998A0 (en) Process for the production of 4-amino-2, 5-bisheterocyclylquinazolines
PL371317A1 (pl) Pochodne acylo-3-karboksyfenylo-mocznika, sposób ich wytwarzania i ich zastosowanie
AU2003218704A8 (en) Process for preparing 2-aminoindan derivatives
AU2002953094A0 (en) Immunomodulating compositions, processes for their production and uses therefor
AP2005003229A0 (en) Process for preparing of paclitaxel.
PL377292A1 (pl) Ulepszony sposób wytwarzania 1,3-podstawionych indenów
SI1487802T1 (sl) 2,3-diaril-pirazolidinski derivati kot inhibitorji encimov, ki razgrajujejo nevrotenzin
AU2003264894A8 (en) Novel method for preparing alpha-glycosylceramides, novel alpha-glycosylceramide derivatives and their uses
IL166374A0 (en) Novel process for producing imidazoÄ1,2-bÜpyridazine derivative
AU2002242942A1 (en) 3-0-'alfa-l-rhamnopyranosyl- (1-2) -alpha-l-rhamnopyranosyl- (1-4) -3beta-d-glucopyranosyl!-25 (s) -spirost an-3beta-ol, process for its isolation, and its use as immunomodulator

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)